Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Talaris Therapeutics Inc (TALS)

Talaris Therapeutics Inc (TALS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Talaris Therapeutics Inc 93 WORCESTER STREET WELLESLEY MA 02481 USA

talaristx.com P: 502-398-9250

Description:

Talaris Therapeutics Inc. is a late-clinical stage cell therapy company. It involved in developing a method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. Talaris Therapeutics Inc. is based in BOSTON.

Key Statistics

Overview:

Market Capitalization, $K 116,318
Enterprise Value, $K 102,648
Shares Outstanding, K 42,764
Annual Sales, $ 0 K
Annual Net Income, $ -73,890 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -14,740 K
EBIT, $ -80,230 K
EBITDA, $ -79,680 K
60-Month Beta 2.18
% of Insider Shareholders 16.50%
% of Institutional Shareholders 67.61%
Float, K 35,708
% Float 83.50%
Short Volume Ratio 0.58

Growth:

1-Year Return 12.40%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 08/14/23
Next Earnings Date 11/09/23
Earnings Per Share ttm -1.64
EPS Growth vs. Prev Qtr 62.96%
EPS Growth vs. Prev Year 54.55%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 10/20/23

TALS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -39.93%
Return-on-Assets % -37.37%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.78
Book Value/Share 3.49
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar